A compound (particularly useful for inhibiting cancer) according to formula I: or a pharmaceutically acceptable salt thereof, wherein:x is 0 or 1;R1-R6 are each independently H, —CN, —NO2, —NO, —OH, halogen, hydroxyalkyl, carboxyl, substituted carboxyl, aminocarbonyl, alkoxy, carbonyl or substituted
A compound (particularly useful for inhibiting cancer) according to formula I: or a pharmaceutically acceptable salt thereof, wherein:x is 0 or 1;R1-R6 are each independently H, —CN, —NO2, —NO, —OH, halogen, hydroxyalkyl, carboxyl, substituted carboxyl, aminocarbonyl, alkoxy, carbonyl or substituted carbonyl;R7 is H, alkyl, alkyl amino, aminoacyl, hydroxyacyl, heteroaryl, heterocycloalkyl, alkyl heteroaryl or alkyl heterocycloalkyl;R8 is H or alkyl;A is O or N; andAr is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, provided that if R7 is H then Ar is aryl substituted with alkyl amino.
대표청구항▼
1. A compound according to formula I: or a pharmaceutically acceptable salt thereof, wherein:x is 0 or 1;R1-R6 are each independently H, —CN, —NO2, —NO, —OH, halogen, hydroxyalkyl, carboxyl, substituted carboxyl, aminocarbonyl, alkoxy, carbonyl or substituted carbonyl;R7 is alkyl, alkyl amino, amino
1. A compound according to formula I: or a pharmaceutically acceptable salt thereof, wherein:x is 0 or 1;R1-R6 are each independently H, —CN, —NO2, —NO, —OH, halogen, hydroxyalkyl, carboxyl, substituted carboxyl, aminocarbonyl, alkoxy, carbonyl or substituted carbonyl;R7 is alkyl, alkyl amino, aminoacyl, hydroxyacyl, heteroaryl, heterocycloalkyl, alkyl heteroaryl or alkyl heterocycloalkyl;R8 is H or alkyl;A is O or N; andAr is represented by formula II: wherein R20 is represented by formula III: wherein R25-R31 are each independently H, halogen, lower alkyl, alkoxy, —O-alkyl amino, —NO2, —N3, carboxyl, substituted carboxyl, alkyl amino, carbonyl, substituted carbonyl, or aminocarbonyl; and R21-R24 are each independently H, halogen, or —CN. 2. The compound of claim 1, wherein R7 is an C1-C4 alkyl; —CzNR40R41, where R40 and R41 can be, independently, hydrogen, alkyl or cycloalkyl, or N, R40 and R41 together form a heterocycloalkyl, and z is 2 to 5; or —CyNR40CyNR40R41, where R40 and R41 can be, independently, hydrogen, alkyl or cycloalkyl, and y is 2 to 5. 3. The compound of claim 1, wherein R7 is C1-C4 alkyl. 4. The compound of claim 1, wherein R7 is —CzNR40R41, where R40 and R41 can be, independently, hydrogen, alkyl or cycloalkyl, or N, R40 and R41 together form a heterocycloalkyl, and z is 2 to 5. 5. The compound of claim 1, wherein R7 is —CyNR40CyNR40R41, where R40 and R41 can be, independently, hydrogen, alkyl or cycloalkyl, and y is 2 to 5. 6. The compound of claim 1, wherein R29 is alkoxy or —O-alkyl amino; and R25-R28 and R30-R31 are each H. 7. The compound of claim 1, wherein R22 is halogen or —CN and R21, R23 and R24 are each H. 8. The compound of claim 1, wherein x is 1. 9. The compound of claim 1, wherein A is O. 10. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: 11. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and at least one pharmaceutically acceptable carrier. 13. The pharmaceutical composition of claim 12, comprising a compound of claim 11. 14. A compound according to formula I: or a pharmaceutically acceptable salt thereof, wherein:x is 0 or 1;R1-R6 are each independently H, —CN, —NO2, —NO, —OH, halogen, hydroxyalkyl, carboxyl, substituted carboxyl, aminocarbonyl, alkoxy, carbonyl or substituted carbonyl;R7 is —CzNR40R41, where R40 and R41 can be, independently, hydrogen, alkyl or cycloalkyl, or N, R40 and R41 together form a heterocycloalkyl, and z is 2 to 5;R8 is H or alkyl;A is O or N; andAr is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl. 15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 14, and at least one pharmaceutically acceptable carrier.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (6)
Boschelli Diane H. (Plymouth MI) Connor David T. (Ann Arbor MI) Khatana Sony S. (Northville MI) Kramer James B. (Sylvania OH) Unangst Paul C. (Ann Arbor MI), 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of.
Saunders, Jeffrey O.; Elbaum, Daniel; Novak, Perry M.; Naegele, Douglas; Bethiel, Randy S.; Ronkin, Steven M.; Badia, Michael C.; Frank, Catharine; Stamos, Dean P.; Walters, William; Pearlman, David, Inhibitors of IMPDH enzyme technical field of the invention.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.